EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Baricitinib Ameliorates Cutaneous Leukocytoclastic Angiitis in Rats

Yui Arata, Naho Ogawa, Suishin Arai, Takumi Abe, Ayana Sasaki, Mizuki Fukuyama, Hiyori Miyatake, Koki Takai, China Washio, Hodaka Ogawa, Ikuma Hori, Yuka Nishibata iD und 4 weitere

Pharmacology Research & Perspectives · 2026-12 · 14 (6)

DOI: 10.1002/prp2.70351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 09.11.2026. Verfasst von Yui Arata und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Azetidines, Sulfonamides, Pyrazoles, Purines. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous leukocytoclastic angiitis (CLA) is a skin‐limited, small‐vessel vasculitis characterized by neutrophil infiltration with leukocytoclastosis. Inflammatory cytokines released from activated neutrophils play crucial roles in the pathogenesis. Glucocorticoids and immunosuppressive drugs are used for treatment. However, susceptibility to infections occurs due to the long‐term administration of these drugs. Therefore, the development of new drugs is desired. A recent study suggested that Janus kinase (JAK)1 and JAK2 are involved in CLA pathogenesis. This pilot study aimed to demonstrate the efficacy of baricitinib that can inhibit both JAK1 and JAK2 on CLA using an animal model. CLA was induced in Wistar Kyoto rats ( n = 7) on Day 0, and these rats were divided randomly into two groups: baricitinib group ( n = 4) and vehicle group ( n = 3). The baricitinib group received baricitinib (10 mg/kg) once daily orally from Days 0 to 6. Skin tissues (four sites/rat) were harvested on Day 7, and histopathological examinations were conducted. The phosphorylation of JAK1 and JAK2 in the inflammatory cells and the amount of IL‐6 secreted in the skin lesion was suppressed by baricitinib. Correspondingly, baricitinib decreased histological scores of CLA represented by a sum of the inflammatory cell infiltration score (0–3) and the leukocytoclastosis score (0, 1) (Vehicle: 2.1 ± 0.4; Baricitinib: 1.5 ± 0.3; p < 0.05). Interestingly, baricitinib suppressed leukocytoclastosis particularly, suggesting that JAK1 or JAK2 might be implicated in the mechanism underlying leukocytoclastosis. This study could serve as a motivation to advance baricitinib to the next stage to examine its efficacy on CLA using a larger number of rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzetidinesSulfonamidesPyrazolesPurinesVasculitis, Leukocytoclastic, CutaneousAnimalsJanus Kinase 1RatsJanus Kinase 2MaleRats, Inbred WKYDisease Models, AnimalPilot ProjectsSkinInterleukin-6

Stichwörter der Autor:innen

JAK inhibitorJanus kinase (JAK)baricitinibcutaneous leukocytoclastic angiitis (CLA)

Substanzen

baricitinibAzetidinesSulfonamidesPyrazolesJanus Kinase 1PurinesJanus Kinase 2Jak2 protein, ratJak1 protein, ratInterleukin-6

Autor:innen und Institutionen

  • Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University, Sapporo, Japan.
  • Department of Surgical Pathology, Hokkaido University Hospital, Sapporo, Japan.
  • Kawakami Dermatology Clinic, Matsudo, Japan.

ORCID-Profile: Yuka Nishibata, Sakiko Masuda, Utano Tomaru, Tamihiro Kawakami, Akihiro Ishizu

Zitieren

APA

Arata, Y., Ogawa, N., Arai, S., Abe, T., Sasaki, A., Fukuyama, M., Miyatake, H., Takai, K., Washio, C., Ogawa, H., Hori, I., Nishibata, Y., Masuda, S., Tomaru, U., Kawakami, T., & Ishizu, A. (2026). Baricitinib Ameliorates Cutaneous Leukocytoclastic Angiitis in Rats. Pharmacology Research & Perspectives, 14(6). https://doi.org/10.1002/prp2.70351

Vancouver

Arata Y, Ogawa N, Arai S, Abe T, Sasaki A, Fukuyama M, et al. Baricitinib Ameliorates Cutaneous Leukocytoclastic Angiitis in Rats. Pharmacology Research & Perspectives. 2026;14(6). doi:10.1002/prp2.70351

BibTeX
@article{Arata2026,
  author = {Arata, Yui and Ogawa, Naho and Arai, Suishin and Abe, Takumi and Sasaki, Ayana and Fukuyama, Mizuki and Miyatake, Hiyori and Takai, Koki and Washio, China and Ogawa, Hodaka and Hori, Ikuma and Nishibata, Yuka and Masuda, Sakiko and Tomaru, Utano and Kawakami, Tamihiro and Ishizu, Akihiro},
  title = {Baricitinib Ameliorates Cutaneous Leukocytoclastic Angiitis in Rats},
  journal = {Pharmacology Research & Perspectives},
  year = {2026},
  volume = {14},
  number = {6},
  doi = {10.1002/prp2.70351}
}
Kostenlos starten →